Abbott Laboratories 8-K/A, filed Jun 9, 2023
Abbott Laboratories (ABT)
About this 8-K/A
Abbott Laboratories filed this 8-K/A on June 9, 2023, reporting on events of April 28, 2023.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in charter)
| (State or other Jurisdiction | (Commission File Number) | (IRS Employer | ||
| of Incorporation) | Identification No.) |
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) |
Name of Each Exchange on
Which |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 — Submission of Matters to a Vote of Security Holders.
On May 2, 2023, Abbott filed a Current Report on Form 8-K summarizing the matters voted on at its Annual Meeting of Shareholders held on April 28, 2023 (the “May 2, 2023 Form 8-K”).
In accordance with the Board of Directors’ recommendation and based on the results of the vote reported under item (4) of the May 2, 2023 Form 8-K, the Board of Directors has determined that Abbott will hold an advisory vote on the compensation of the named executive officers listed in the proxy statement for its Annual Meeting of Shareholders annually.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||
| Date: June 9, 2023 | By: | /s/ Robert E. Funck, Jr. |
| Robert E. Funck, Jr. | ||
| Executive Vice President, Finance and Chief Financial Officer | ||